Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $421.80, for a total value of $9,490,500.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, September 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $416.35, for a total value of $9,367,875.00.
• On Monday, September 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $400.56, for a total value of $9,012,600.00.
• On Monday, September 8th, Michael Benkowitz sold 5,000 shares of United Therapeutics stock. The stock was sold at an average price of $392.21, for a total value of $1,961,050.00.
• On Tuesday, September 9th, Michael Benkowitz sold 11,375 shares of United Therapeutics stock. The stock was sold at an average price of $397.41, for a total value of $4,520,538.75.
• On Tuesday, September 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00.

United Therapeutics Stock Up 2.2%

Shares of NASDAQ UTHR opened at $453.07 on Friday. The business’s 50 day moving average price is $356.31 and its two-hundred day moving average price is $319.01. The company has a market cap of $20.44 billion, a PE ratio of 17.68, a price-to-earnings-growth ratio of 6.76 and a beta of 0.66. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $455.12.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same period in the previous year, the company posted $5.85 EPS. United Therapeutics’s revenue for the quarter was up 11.7% compared to the same quarter last year. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on UTHR shares. Morgan Stanley decreased their target price on United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. Jefferies Financial Group increased their price target on United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. UBS Group increased their price target on United Therapeutics from $560.00 to $580.00 and gave the stock a “buy” rating in a research report on Monday. Royal Bank Of Canada initiated coverage on United Therapeutics in a research report on Friday, September 26th. They set an “outperform” rating and a $569.00 price target on the stock. Finally, Oppenheimer increased their price target on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Ten analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $449.57.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of UTHR. Two Sigma Investments LP lifted its stake in shares of United Therapeutics by 3.0% in the 4th quarter. Two Sigma Investments LP now owns 1,773 shares of the biotechnology company’s stock valued at $626,000 after acquiring an additional 52 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of United Therapeutics by 15.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,643 shares of the biotechnology company’s stock valued at $1,991,000 after acquiring an additional 769 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of United Therapeutics by 29,415.2% in the 1st quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company’s stock valued at $68,422,000 after acquiring an additional 221,202 shares during the last quarter. Unigestion Holding SA bought a new position in shares of United Therapeutics in the 1st quarter valued at $2,672,000. Finally, Hennion & Walsh Asset Management Inc. raised its position in United Therapeutics by 84.7% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 4,297 shares of the biotechnology company’s stock worth $1,325,000 after purchasing an additional 1,970 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.